

ORAL PRESENTATION

Open Access

# Longitudinal performance of polycaprolactone-based scaffold plus recombinant human morphogenetic protein-2 (rhBMP-2) in large preclinical animal model: 6- versus 12 months

Mostyn RNO Yong<sup>1,2\*</sup>, Flavia M Savi<sup>2</sup>, Maria A Woodruff<sup>2</sup>, Siamak Saifzadeh<sup>2</sup>, Geoffrey N Askin<sup>1,2</sup>, Robert D Labrom<sup>1,2</sup>, Dietmar W Hutmacher<sup>2</sup>, Clayton J Adam<sup>1,2</sup>

From The 10th Meeting of the International Research Society of Spinal Deformities (IRSSD 2014 Sapporo) Sapporo, Japan. 29 June - 2 July 2014

## Objectives

There is strong current interest in the use of biodegradable scaffolds in combination with bone growth factors as a valuable alternative to the current gold standard autograft in spinal fusion surgery (Yong et al. 2013). Here we report on 6- vs 12- month data set evaluating the longitudinal performance of a CaP coated polycaprolactone (PCL) scaffold loaded with recombinant human bone morphogenetic protein-2 (rhBMP-2) as a bone graft substitute within a preclinical ovine thoracic spine.

## Material and methods

Twelve sheep underwent a 3-level (T6/7, T8/9 and T10/11) discectomy with randomly allocated implantation of a different graft substitute at each of the three levels; (i) calcium phosphate (CaP) coated polycaprolactone based scaffold plus 0.54mcg rhBMP-2, (ii) CaP coated PCL- based scaffold alone or (iii) autograft (mulched rib head). Fusion assessments were performed via high resolution clinical computed tomography and histological evaluation were undertaken at six (n=6) and twelve (n=6) months post-surgery using the Sucato grading system (Sucato et al. 2004).

## Results

The computed tomography fusion grades of the 6- and 12- months in the rhBMP-2 plus PCL- based scaffold group were 1.9 and 2.1 respectively, in the autograft

group 1.9 and 1.3 respectively, and in the scaffold alone group 0.9 and 1.17 respectively. There were no statistically significant differences in the fusion scores between 6- and 12- month for the rhBMP plus PCL- based scaffold or PCL - based scaffold alone group however there was a significant reduction in scores in the autograft group. These scores were seen to correlate with histological evaluations of the respective groups.

## Conclusions

The results of this study demonstrate the efficacy of scaffold-based delivery of rhBMP-2 in promoting higher fusion grades at 6- and 12- months in comparison to the scaffold alone or autograft group within the same time frame. Fusion grades achieved at six months using PCL+rhBMP-2 are not significantly increased at twelve months post surgery.

## Authors' details

<sup>1</sup>QUT/Mater Paediatric Spine Research Group, Queensland University of Technology, Mater Misericordiae Health Services, Brisbane, Queensland, Australia. <sup>2</sup>Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.

Published: 19 January 2015

## References

1. Sucato DJ, Hedequist D, Zhang H, Pierce W, O'Brien SE, Welch RD: Recombinant Human Bone Morphogenetic Protein - 2 Enhances Anterior Spinal Fusion in a Thoroscopically Instrumented Animal Model. *The Journal of Bone and Joint Surgery American Volume* 2004, **86-A**(4):752-762.
2. Yong MRNO, Saifzadeh S, Askin GN, Labrom RD, Hutmacher DW, Adam CJ: Biological Performance of a Polycaprolactone -based Scaffold plus Recombinant Human Morphogenetic Protein - 2 (rhBMP-2) in an Ovine

<sup>1</sup>QUT/Mater Paediatric Spine Research Group, Queensland University of Technology, Mater Misericordiae Health Services, Brisbane, Queensland, Australia

Full list of author information is available at the end of the article

Thoracic Interbody Fusion Model. *European Spine Journal* 2013, DOI  
10.1007/s00586-013-2085-x.

doi:10.1186/1748-7161-10-S1-O58

**Cite this article as:** Yong *et al.*: Longitudinal performance of polycaprolactone-based scaffold plus recombinant human morphogenetic protein-2 (rhBMP-2) in large preclinical animal model: 6-versus 12 months. *Scoliosis* 2015 **10**(Suppl 1):O58.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

